New findings and unique aspects in pediatric aspergillosis

References

• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366
   PubMed Web of Science ®Google Scholar
• Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406–1412
   PubMed Web of Science ®Google Scholar
• Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135–144
   PubMed Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 2000; 79: 250–260
   PubMed Web of Science ®Google Scholar
• Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J Infect 1998; 37: 173–180
   PubMed Web of Science ®Google Scholar
• Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147–1200
   PubMedGoogle Scholar
• Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–615
   PubMed Web of Science ®Google Scholar
• Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicenter survey in the greater Paris area. J Hosp Infect 2002; 51: 288–296
   PubMed Web of Science ®Google Scholar
• Yuen KY, Woo PCY, Ip MSM, et al. Stage-specific manifestations of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997; 25: 37–42
   PubMed Web of Science ®Google Scholar
• Kruger W, Russmann B, Kroger N, et al. Early infections in patients undergoing bone marrow or blood stem cell transplantation – a 7 year single centre investigation of 409 cases. Bone Marrow Transplant 1999; 23: 589–597
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Cater RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827–833
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917
   PubMed Web of Science ®Google Scholar
• Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000; 26: 999–1004
   PubMed Web of Science ®Google Scholar
• Benjamin DKJ, Miller WC, Bayliff S, et al. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002; 21: 227–234
   PubMed Web of Science ®Google Scholar
• Kume H, Yamazaki T, Abe M, et al. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: Comparison of data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993, and 1997. Pathol Int 2003; 53: 744–750
   PubMed Web of Science ®Google Scholar
• Lin S-J, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systemic review of the literature. Clin Infect Dis 2000; 32: 358–366
   Web of Science ®Google Scholar
• Walmsley S, Devi S, King S, et al. Invasive Aspergillus infections in a pediatric hospital: a ten year review. Pediatr Infect Dis J 1993; 12: 673–682
   PubMedGoogle Scholar
• Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis 1999; 29: 1210–1219
   PubMed Web of Science ®Google Scholar
• Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33: 1824–1833
   PubMed Web of Science ®Google Scholar
• Gefter WB, Albelda SM, Talbot GH, et al. Invasive pulmonary aspergillosis and acute leukemia: limitations in the diagnostic utility of the air crescent sign. Radiology 1985; 157: 605–610
   PubMed Web of Science ®Google Scholar
• Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr Radiol 2003; 33: 453–460
   PubMed Web of Science ®Google Scholar
• Allan BT, Patton D, Ramsey NKC, Day DL. Pulmonary fungal infections after bone marrow transplantation. Pediatric Radiol 1988; 18: 118–122
   PubMed Web of Science ®Google Scholar
• Taccone A, Occhi M, Garaventa A, Manfredini L, Viscoli C. CT of invasive pulmonary aspergillosis in children with cancer. Pediatric Radiol 1993; 23: 177–180
   PubMed Web of Science ®Google Scholar
• Sulahian A, Tabouret M, Ribaud P, et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis 1996; 15: 139–145
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 7: 1898–1906
   Google Scholar
• Mennink-Kersten MASH, Klont RR, Warris A, Op den Camp HJM, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 2004; 363: 325–327
   PubMed Web of Science ®Google Scholar
• Warris, A, Abrahamsen, TG, Breuker, IM, , et al. Fungal antigenemia in premature neonates due to the presence of galactomannan and mannan in milk formulas. Program and Abstracts of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Washington, DC, 2001: Abstract J–848.
   Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–1396
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999; 18: 702–708
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240–248
   PubMed Web of Science ®Google Scholar